Gladice Wallraven

488 total citations
19 papers, 297 citations indexed

About

Gladice Wallraven is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, Gladice Wallraven has authored 19 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Immunology and 5 papers in Biotechnology. Recurrent topics in Gladice Wallraven's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Gladice Wallraven is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Gladice Wallraven collaborates with scholars based in United States. Gladice Wallraven's co-authors include John Nemunaitis, Neil Senzer, Minal Barve, Staci Horvath, Luisa Manning, Robert Mennel, Beena O. Pappen, Ernest Bognar, Laura Stanbery and Carl Lenarsky and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Gladice Wallraven

18 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gladice Wallraven United States 11 206 119 109 64 52 19 297
Staci Horvath United States 10 174 0.8× 89 0.7× 107 1.0× 43 0.7× 39 0.8× 14 248
Marianna Buttarelli Italy 13 129 0.6× 179 1.5× 38 0.3× 37 0.6× 88 1.7× 19 320
Abhilasha Sinha United States 12 134 0.7× 188 1.6× 72 0.7× 46 0.7× 55 1.1× 17 300
Ashleigh Herriott United Kingdom 4 359 1.7× 255 2.1× 33 0.3× 57 0.9× 59 1.1× 6 407
Shamima Yeasmin Japan 10 115 0.6× 289 2.4× 24 0.2× 42 0.7× 123 2.4× 19 442
Matthew Ballew United States 3 270 1.3× 321 2.7× 199 1.8× 48 0.8× 70 1.3× 3 499
Andrea Walens United States 10 194 0.9× 173 1.5× 138 1.3× 43 0.7× 82 1.6× 18 370
Baihua Luo China 14 112 0.5× 218 1.8× 69 0.6× 42 0.7× 164 3.2× 17 377
Lilia Merida de Long Australia 9 115 0.6× 225 1.9× 21 0.2× 50 0.8× 69 1.3× 16 317
Nicholas Badham United Kingdom 2 185 0.9× 271 2.3× 22 0.2× 26 0.4× 46 0.9× 2 328

Countries citing papers authored by Gladice Wallraven

Since Specialization
Citations

This map shows the geographic impact of Gladice Wallraven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gladice Wallraven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gladice Wallraven more than expected).

Fields of papers citing papers by Gladice Wallraven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gladice Wallraven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gladice Wallraven. The network helps show where Gladice Wallraven may publish in the future.

Co-authorship network of co-authors of Gladice Wallraven

This figure shows the co-authorship network connecting the top 25 collaborators of Gladice Wallraven. A scholar is included among the top collaborators of Gladice Wallraven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gladice Wallraven. Gladice Wallraven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Willoughby, David, Ernest Bognar, Laura Stanbery, et al.. (2025). Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product. Scientific Reports. 15(1). 8637–8637. 1 indexed citations
2.
Nemunaitis, John, Laura Stanbery, Gladice Wallraven, et al.. (2024). Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future Oncology. 20(29). 2149–2164. 1 indexed citations
3.
Anderson, Peter M., Brian D. Crompton, Kelly Klega, et al.. (2023). Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clinical Cancer Research. 29(9). 1689–1697. 15 indexed citations
4.
Barve, Minal, Phylicia Aaron, Luisa Manning, et al.. (2022). Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights Oncology. 16. 1363231461–1363231461. 15 indexed citations
5.
Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 161(3). 676–680. 26 indexed citations
6.
Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 163(3). 459–464. 14 indexed citations
7.
Adams, Ned, Laura Stanbery, Luisa Manning, et al.. (2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 9(10). 1201–1201. 6 indexed citations
8.
Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2021). Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Therapy. 29(3-4). 369–382. 20 indexed citations
9.
Oh, Jonathan, Minal Barve, Neil Senzer, et al.. (2020). Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecologic Oncology Reports. 34. 100648–100648. 19 indexed citations
10.
Herron, James N., Laura Stanbery, Phylicia Aaron, et al.. (2020). Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response. 3(4). 14 indexed citations
11.
Rocconi, Rodney P., Jennifer Scalici, Minal Barve, et al.. (2018). Phase I trial of Vigil® personalized engineered autologous tumor cells (EATC) in ovarian cancer. Gynecologic Oncology. 149. 40–41. 1 indexed citations
12.
Manning, Luisa, Minal Barve, Gladice Wallraven, et al.. (2017). Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors. 2(1). 3 indexed citations
13.
Anderson, Peter M., Minal Barve, Jonathan Gill, et al.. (2017). A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS11079–TPS11079. 1 indexed citations
14.
Stephens, Philip J., Robert Mennel, Minal Barve, et al.. (2017). Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. Journal of Pediatric Hematology/Oncology. 39(4). e183–e186. 14 indexed citations
15.
Barve, Minal, Robert Mennel, Carl Lenarsky, et al.. (2016). Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Molecular Therapy. 24(8). 1478–1483. 71 indexed citations
16.
Barve, Minal, Joseph A. Kuhn, Peter D. Beitsch, et al.. (2016). Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. 1(4). 10 indexed citations
17.
Barve, Minal, Zhaohui Wang, Padmasini Kumar, et al.. (2015). Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer. Molecular Therapy. 23(6). 1123–1130. 14 indexed citations
18.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy. 23(6). 1103–1109. 48 indexed citations
19.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot trial of vigil immunotherapy in Ewing’s sarcoma.. Journal of Clinical Oncology. 33(15_suppl). 10522–10522. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Staci Horvath Breakdown of academic impact, for papers by Marianna Buttarelli Breakdown of academic impact, for papers by Abhilasha Sinha Breakdown of academic impact, for papers by Ashleigh Herriott Breakdown of academic impact, for papers by Shamima Yeasmin Breakdown of academic impact, for papers by Matthew Ballew Breakdown of academic impact, for papers by Andrea Walens Breakdown of academic impact, for papers by Baihua Luo Breakdown of academic impact, for papers by Lilia Merida de Long Breakdown of academic impact, for papers by Nicholas Badham
Rankless by CCL
2026